A Game-Changer for Diabetes: Polymer Delivers Insulin Painlessly Through Skin
November 25, 2025
Background
Allergic rhinitis, commonly known as hay fever, is an allergic reaction when the immune system overreacts to environmental allergens. It is a common condition that affects a significant portion of the population worldwide. Seasonal allergic rhinitis, also known as hay fever, occurs during specific seasons when certain plants release pollen into the air.
Common triggers include tree pollen in spring, grass pollen in summer, and weed pollen in fall. Perennial allergic rhinitis is a type of allergic rhinitis that persists throughout the year and is usually caused by indoor allergens such as dust mites, pet dander, mold, or cockroach allergens.
Epidemiology
Allergic rhinitis is a common condition, and its prevalence varies across different populations and geographical locations. According to estimates, allergic rhinitis affects approximately 10-30% of adults and up to 40% of children worldwide. The prevalence can be higher in urban areas and industrialized countries. The incidence of allergic rhinitis refers to the rate of new cases developing within a specific period. It can vary depending on age, genetics, environmental exposure, and geographical location.
The incidence tends to be higher in children and adolescents, with the condition often developing during early childhood. Specific allergens in the environment primarily trigger seasonal allergic rhinitis during certain seasons. Different types of pollen can cause symptoms during different times of the year. For example, tree pollen allergies are more common in spring, grass pollen allergies in summer, and weed pollen allergies in fall.
However, it’s important to note that perennial allergic rhinitis, triggered by indoor allergens, can occur year-round and is not limited to specific seasons. Allergic rhinitis can affect both males and females, but some studies suggest it may be more prevalent in males during childhood. In contrast, females may have a higher prevalence during adulthood. The reasons for these gender differences are not yet fully understood and may involve complex interactions between genetic, hormonal, and environmental factors.
Anatomy
Pathophysiology
Sensitization is the initial step in the development of allergic rhinitis. It occurs when an individual is first exposed to an allergen, such as pollen or dust mites. The allergen enters the body, typically through inhalation, and comes into contact with immune cells called antigen-presenting cells (APCs). The APCs process the allergen and present it to another type of immune cell known as a T-lymphocyte (T-cell). The T-lymphocytes, specifically a subset called T-helper 2 (Th2) cells, recognize the allergen presented by the APCs. Upon activation, the Th2 cells release chemical signals called cytokines, particularly interleukin-4 (IL-4), interleukin-5 (IL-5), and interleukin-13 (IL-13).
These cytokines play a crucial role in orchestrating the subsequent immune response. IL-4 stimulates B-lymphocytes to produce and release large amounts of immunoglobulin E (IgE) antibodies specific to the allergen. IgE antibodies are specialized molecules that bind to mast cells and basophils, which are types of immune cells found in tissues throughout the body, including the nasal passages. During subsequent exposures to the same allergen, the allergen binds to the specific IgE antibodies attached to the mast cells and basophils.
This triggers the release of various chemical mediators from these cells, such as histamine, leukotrienes, and prostaglandins. Releasing chemical mediators leads to an inflammatory response in the nasal mucosa. Histamine causes blood vessels to dilate, leading to nasal congestion and swelling. It also triggers itching and stimulates the production of mucus. Leukotrienes and prostaglandins contribute to increased mucus production, bronchoconstriction, and further inflammation.
Etiology
The etiology of allergic rhinitis involves a combination of genetic predisposition and environmental factors.
Genetics
Prognostic Factors
The prognosis of allergic rhinitis is generally good as it is a chronic condition that can be managed effectively with appropriate treatment and lifestyle modifications.
Clinical History
A comprehensive and detailed medical history is crucial in assessing allergic rhinitis (AR). It is important to ask specific questions about the nature of symptoms, their timing, duration, and frequency, any potential exposures, factors that worsen or alleviate symptoms, and any observed seasonal patterns.
Individuals with intermittent or seasonal AR commonly experience sneezing, rhinorrhea, and watery eyes. On the other hand, patients with chronic AR often present with complaints of postnasal drip, persistent nasal congestion, and obstruction. These individuals frequently have a family history of allergic rhinitis or a personal history of asthma.
Patients with intermittent rhinitis may provide information about triggers that initiate their symptoms, including allergens like pollen, animal dander, mold, dust mites, and irritants such as certain flooring or upholstery materials, high humidity levels, strong perfumes, or exposure to tobacco smoke.
Physical Examination
While the diagnosis of allergic rhinitis is primarily based on clinical history, physical examination findings can provide additional information. The provider may observe nasal congestion or swelling of the nasal passages. The presence of clear, watery nasal discharge (rhinorrhea) may be noted. The provider may observe redness or swelling of the conjunctiva, the thin membrane covering the white part of the eyes.
Excessive tearing or watery eyes (epiphora) may be noted. Signs of postnasal drip and mucus dripping down the back of the throat can be observed. This can lead to throat irritation or cough. Dark circles or puffiness under the eyes, known as allergic shiners, may be present due to congestion of blood vessels in the area.
Age group
Associated comorbidity
Associated activity
Acuity of presentation
Differential Diagnoses
Vasomotor Rhinitis
Infectious Rhinitis
Nasopharyngeal Neoplasm
Nasal Polyposis
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
Identify and try to avoid allergens that trigger your symptoms. This may involve taking steps such as using dust mite-proof covers on bedding, keeping windows closed during high pollen seasons, and avoiding outdoor activities when pollen counts are high.
Medications such as antihistamines, nasal corticosteroids, and leukotriene receptor antagonists are commonly prescribed. Also, rinsing the nasal passages with a saltwater solution can help reduce nasal congestion and remove allergens and thin mucus.
by Stage
by Modality
Chemotherapy
Radiation Therapy
Surgical Interventions
Hormone Therapy
Immunotherapy
Hyperthermia
Photodynamic Therapy
Stem Cell Transplant
Targeted Therapy
Palliative Care
Medication
20 mg orally once each day
Do not increase the dose to more than 20 mg each day
pseudoephedrine/desloratadineÂ
Clarinex-D 12 hr- 1 tablet (120mg/2.5mg) orally every 12 hours
Clarinex-D 24 hr- 1 tablet (240mg/5mg) orally every 24 hours
grass pollens allergen extractÂ
Indicated for Allergic Rhinitis
Start therapy four months prior to the expected beginning of every grass pollen season and also continue for the entire period of grass pollen season
Age 18-65 years
300 IR (index of reactivity) by sublingual route every day. Administer the first dose in the physician office and also keep in observation for nearly 30 min
QNASL: Administer 2 sprays in each nostril every day.
Do not exceed 320 mcg/day of total daily dose.
Beconase AQ: Administer 1 to 2 sprays in each nostril twice a day
Do not exceed 168-336 mcg/day of total daily dose.
Vasomotor Rhinitis/ Nasal Polyps (Postsurgical Prophylaxis)
Beconase AQ: Administer 1 to 2 sprays in each nostril twice a day
Spray the suspension in every nostril twice daily
Increase the dose to 3-4 each day if required
Administer 10ml thrice or four times a day
Do not exceed 40ml in a day
The recommended dose is 225 mg twice a day
Indicated for Allergic rhinitis
10 mg orally one time a day
It should not exceed 10 mg in a day
Urticaria, chronic spontaneous
10 mg orally one time a day
If the symptoms control is insufficient; the dose may enhance to 20 mg one time a day
Indicated for Allergic Rhinitis
The suggested dose is 8 mg to 16 mg two times a day
Indicated for Urticaria, Allergic rhinitis
10 mg orally every day
Take one tablet in a day orally for a week
2 to 3 drops Intranasally in each nostril given 2 to 3 times a day
Take a dose of 8 mg orally as required up to three times a day
Take 1-2 mg by oral route two times daily
10 mg is given orally on empty stomach once a day
The usual dose, which is recommended via oral administration, is 60 – 120 mg daily in the morning, or it can be taken as 60 mg daily two times with a maximum dose of 120 mg in a day
Dose Adjustments
Renal Dose Adjustment
In case of renal insufficiency, the dose of terfenadine will be reduced to half the daily dose, which is recommended as the usual dose is 30 mg daily two times if the CrCl falls below 40 mL/min
Put 1 spray in each nostril every 6 to 8 hours and it may raise to 6 times in a day
Administer 20mg tablet daily once
A prescription drug called ipratropium Intranasal is used to treat runny nose brought on by the common cold and seasonal allergy symptoms
Allergic and Nonallergic Perennial Rhinitis Associated with Rhinorrhea:
0.03%: per day, two or three times, each nostril two sprays
Seasonal Allergic Rhinitis and Associated Rhinorrhea: 0.06%:
per day four times, two sprays each nostril
Associated Rhinorrhea and the Common Cold:
0.06%: each nostril two sprays every 6 to 8 hours
Dose Adjustments
Limited data is available
Histex:The recommended dose is 2.5 mg equivalent to 5 ml orally every four times a day
M-Hist PD or Vanahist PD:The recommended dose is 2.5 mg equivalent to 5 ml orally every four times a day
It is an investigational drug
The drug is a JAK inhibitor which is studied for its anti-inflammatory properties
Take a dose of 4 mg orally every 4 to 6 hours
Maximum dose should not be more than six tablets in a day
5 mg to 10 mg once a day orally
Maximum dose is 10 mg per day
Rosmarinic acid is a plant-based compound. It is well known as the active ingredient in Rosemary and Perilla oil
Allergic/Non-allergic:
Fluticasone furoate 27.5 mcg/spray or Fluticasone propionate 50 mcg/spray):
2 sprays in each nostril once a day
Note: Reduce 1 spray in each nostril upon controlled symptoms
levocetirizine/montelukast/ambroxolÂ
One tablet orally every day
Initial dose: Administer 1 spray in each nostril every day
Do not exceed 4 sprays in each nostril for a day
For children 4-11 years, 10 mg once daily
For children more than 12 years, 20 mg once daily
pseudoephedrine/desloratadineÂ
Clarinex-D 12 hr- 1 tablet (120mg/2.5mg) orally every 12 hours
Clarinex-D 24 hr- 1 tablet (240mg/5mg) orally every 24 hours
grass pollens allergen extractÂ
Indicated for Allergic Rhinitis
Age 5-17 years
Start therapy four months prior to the expected beginning of every grass pollen season and also continue for the entire period of grass pollen season
Day-1: 300 IR (index of reactivity) by sublingual route one time. Administer the first dose in the physician office and also keep in observation for nearly 30 min
Day-2: 200 IR (index of reactivity) by sublingual route one time
Day-3 and afterward: 300 IR (index of reactivity) by sublingual route every day.
Age <5 years
Safety and efficacy not established
QNASL
≥12 years: Administer 2 sprays in each nostril every day.
<4 years: Safety and efficacy not established.
4-11 years: Administer 1 spray in each nostril every day.
Do not exceed 80 mcg/day.
Beconase AQ
12 years: Administer 1 to 2 sprays in each nostril twice a day.
6 to 11 years: Administer 1 spray in each nostril twice daily. In individuals who are not effectively responding or have more severe symptoms, the dosage may be increased to 2 sprays in each nostril.
<6 years: Safety and efficacy not established.
For more than 9 years- Spray the suspension in every nostril twice daily
Increase the dose to 3-4 each day if required
Discontinue the product if no effect is seen in 3 days
Administer 10ml thrice or four times a day
Do not exceed 40ml in a day
Indicated for Allergic rhinitis
Age 2-12 years
Body weight 10 Kg-25 Kg: 2.5 mg orally one time a day
Body weight >25 Kg: 5 mg orally one time a day
Age >12 years
10 mg orally one time a day
Urticaria, chronic spontaneous
Age 2-12 years
Body weight 10 Kg-25 Kg: 2.5 mg orally one time a day
Body weight >25 Kg: 5 mg orally one time a day
Age >12 years
10 mg orally one time a day
Indicated for Urticaria, Allergic rhinitis
Age >12 years
10 mg orally every day
for 13 to 18 years old:
Take one tablet in a day orally for a week
For >12years old:
Take a dose of 8 mg orally as required up to three times a day
Age more than or equal to 12 years
Take 1-2 mg by oral route two times daily
Pediatric patients who are above 12 with a weight of more than 50 kg should be given 60-120 mg via oral administration, or it can be taken two times a day with 60 mg each time
For <2 years old: Safety and efficacy not determined
For ≥2 years old:
Put 1 spray in each nostril every 6 to 8 hours and it may raise to 6 times in a day
6 to 11 years (Weighing at least 20 kgs): Administer 10mg tablet daily once
≥12 years: Administer 20mg tablet daily once
It is used to treat runny nose brought on by the common cold and seasonal allergy symptoms
Allergic and Nonallergic Perennial Rhinitis Associated with Rhinorrhea:
Ages six or older:
0.03%: per day, two or three times, each nostril two sprays
Seasonal Allergic Rhinitis Associated with Rhinorrhea:
Ages five or above:
0.06%: Four times a day, two sprays per nostril
Associated Rhinorrhea and the Common Cold:
0.05%:
Ages 5 to 11: each nostril two sprays thrice each day
Ages 12 and up: each nostril two sprays every 6 to 8 hours
Histex
For age years 6 -<12
The recommended dose is 1.25 mg equivalent to 2.5 ml orally four times a day or as needed
For age years ≥12
The recommended dose is 2.5 mg equivalent to 5 ml orally four times a day
M-Hist PD or Vanahist PD
For age Years 6 -<12 years
The recommended dose is 1.25 mg equivalent to 2 ml orally four times a day or as needed
For age years ≥12
The recommended dose is 2.5 mg equivalent to 4 ml orally four times a day
For >12 years old:
Take a dose of 4 mg orally every 4 to 6 hours
For 6 to 12 years old:
Take a dose of one-half tablet of 4 mg orally every 4 to 6 hours
Fluticasone furoate:
For Children 2 to 11 years: 1 spray (55 mcg) per nostril once a day
Increase the dose to 2 sprays (110 mcg) per nostril depending on the symptoms
Fluticasone propionate:
For Children 4 to 11 years: 1 to 2 sprays (100 to 200 mcg/day) per nostril once a day (do not exceed 2 sprays (total dose 400 mcg/day) per nostril once a day)
Initial dose: Administer 1 spray in each nostril every day
6 to 11 years: Do not exceed 2 sprays in each nostril for a day
≥12 years: Do not exceed 4 sprays in each nostril for a day
<6 years: Safety and efficacy not established
Future Trends
References
Allergic rhinitis, commonly known as hay fever, is an allergic reaction when the immune system overreacts to environmental allergens. It is a common condition that affects a significant portion of the population worldwide. Seasonal allergic rhinitis, also known as hay fever, occurs during specific seasons when certain plants release pollen into the air.
Common triggers include tree pollen in spring, grass pollen in summer, and weed pollen in fall. Perennial allergic rhinitis is a type of allergic rhinitis that persists throughout the year and is usually caused by indoor allergens such as dust mites, pet dander, mold, or cockroach allergens.
Allergic rhinitis is a common condition, and its prevalence varies across different populations and geographical locations. According to estimates, allergic rhinitis affects approximately 10-30% of adults and up to 40% of children worldwide. The prevalence can be higher in urban areas and industrialized countries. The incidence of allergic rhinitis refers to the rate of new cases developing within a specific period. It can vary depending on age, genetics, environmental exposure, and geographical location.
The incidence tends to be higher in children and adolescents, with the condition often developing during early childhood. Specific allergens in the environment primarily trigger seasonal allergic rhinitis during certain seasons. Different types of pollen can cause symptoms during different times of the year. For example, tree pollen allergies are more common in spring, grass pollen allergies in summer, and weed pollen allergies in fall.
However, it’s important to note that perennial allergic rhinitis, triggered by indoor allergens, can occur year-round and is not limited to specific seasons. Allergic rhinitis can affect both males and females, but some studies suggest it may be more prevalent in males during childhood. In contrast, females may have a higher prevalence during adulthood. The reasons for these gender differences are not yet fully understood and may involve complex interactions between genetic, hormonal, and environmental factors.
Sensitization is the initial step in the development of allergic rhinitis. It occurs when an individual is first exposed to an allergen, such as pollen or dust mites. The allergen enters the body, typically through inhalation, and comes into contact with immune cells called antigen-presenting cells (APCs). The APCs process the allergen and present it to another type of immune cell known as a T-lymphocyte (T-cell). The T-lymphocytes, specifically a subset called T-helper 2 (Th2) cells, recognize the allergen presented by the APCs. Upon activation, the Th2 cells release chemical signals called cytokines, particularly interleukin-4 (IL-4), interleukin-5 (IL-5), and interleukin-13 (IL-13).
These cytokines play a crucial role in orchestrating the subsequent immune response. IL-4 stimulates B-lymphocytes to produce and release large amounts of immunoglobulin E (IgE) antibodies specific to the allergen. IgE antibodies are specialized molecules that bind to mast cells and basophils, which are types of immune cells found in tissues throughout the body, including the nasal passages. During subsequent exposures to the same allergen, the allergen binds to the specific IgE antibodies attached to the mast cells and basophils.
This triggers the release of various chemical mediators from these cells, such as histamine, leukotrienes, and prostaglandins. Releasing chemical mediators leads to an inflammatory response in the nasal mucosa. Histamine causes blood vessels to dilate, leading to nasal congestion and swelling. It also triggers itching and stimulates the production of mucus. Leukotrienes and prostaglandins contribute to increased mucus production, bronchoconstriction, and further inflammation.
The etiology of allergic rhinitis involves a combination of genetic predisposition and environmental factors.
The prognosis of allergic rhinitis is generally good as it is a chronic condition that can be managed effectively with appropriate treatment and lifestyle modifications.
A comprehensive and detailed medical history is crucial in assessing allergic rhinitis (AR). It is important to ask specific questions about the nature of symptoms, their timing, duration, and frequency, any potential exposures, factors that worsen or alleviate symptoms, and any observed seasonal patterns.
Individuals with intermittent or seasonal AR commonly experience sneezing, rhinorrhea, and watery eyes. On the other hand, patients with chronic AR often present with complaints of postnasal drip, persistent nasal congestion, and obstruction. These individuals frequently have a family history of allergic rhinitis or a personal history of asthma.
Patients with intermittent rhinitis may provide information about triggers that initiate their symptoms, including allergens like pollen, animal dander, mold, dust mites, and irritants such as certain flooring or upholstery materials, high humidity levels, strong perfumes, or exposure to tobacco smoke.
While the diagnosis of allergic rhinitis is primarily based on clinical history, physical examination findings can provide additional information. The provider may observe nasal congestion or swelling of the nasal passages. The presence of clear, watery nasal discharge (rhinorrhea) may be noted. The provider may observe redness or swelling of the conjunctiva, the thin membrane covering the white part of the eyes.
Excessive tearing or watery eyes (epiphora) may be noted. Signs of postnasal drip and mucus dripping down the back of the throat can be observed. This can lead to throat irritation or cough. Dark circles or puffiness under the eyes, known as allergic shiners, may be present due to congestion of blood vessels in the area.
Vasomotor Rhinitis
Infectious Rhinitis
Nasopharyngeal Neoplasm
Nasal Polyposis
Identify and try to avoid allergens that trigger your symptoms. This may involve taking steps such as using dust mite-proof covers on bedding, keeping windows closed during high pollen seasons, and avoiding outdoor activities when pollen counts are high.
Medications such as antihistamines, nasal corticosteroids, and leukotriene receptor antagonists are commonly prescribed. Also, rinsing the nasal passages with a saltwater solution can help reduce nasal congestion and remove allergens and thin mucus.
Allergic rhinitis, commonly known as hay fever, is an allergic reaction when the immune system overreacts to environmental allergens. It is a common condition that affects a significant portion of the population worldwide. Seasonal allergic rhinitis, also known as hay fever, occurs during specific seasons when certain plants release pollen into the air.
Common triggers include tree pollen in spring, grass pollen in summer, and weed pollen in fall. Perennial allergic rhinitis is a type of allergic rhinitis that persists throughout the year and is usually caused by indoor allergens such as dust mites, pet dander, mold, or cockroach allergens.
Allergic rhinitis is a common condition, and its prevalence varies across different populations and geographical locations. According to estimates, allergic rhinitis affects approximately 10-30% of adults and up to 40% of children worldwide. The prevalence can be higher in urban areas and industrialized countries. The incidence of allergic rhinitis refers to the rate of new cases developing within a specific period. It can vary depending on age, genetics, environmental exposure, and geographical location.
The incidence tends to be higher in children and adolescents, with the condition often developing during early childhood. Specific allergens in the environment primarily trigger seasonal allergic rhinitis during certain seasons. Different types of pollen can cause symptoms during different times of the year. For example, tree pollen allergies are more common in spring, grass pollen allergies in summer, and weed pollen allergies in fall.
However, it’s important to note that perennial allergic rhinitis, triggered by indoor allergens, can occur year-round and is not limited to specific seasons. Allergic rhinitis can affect both males and females, but some studies suggest it may be more prevalent in males during childhood. In contrast, females may have a higher prevalence during adulthood. The reasons for these gender differences are not yet fully understood and may involve complex interactions between genetic, hormonal, and environmental factors.
Sensitization is the initial step in the development of allergic rhinitis. It occurs when an individual is first exposed to an allergen, such as pollen or dust mites. The allergen enters the body, typically through inhalation, and comes into contact with immune cells called antigen-presenting cells (APCs). The APCs process the allergen and present it to another type of immune cell known as a T-lymphocyte (T-cell). The T-lymphocytes, specifically a subset called T-helper 2 (Th2) cells, recognize the allergen presented by the APCs. Upon activation, the Th2 cells release chemical signals called cytokines, particularly interleukin-4 (IL-4), interleukin-5 (IL-5), and interleukin-13 (IL-13).
These cytokines play a crucial role in orchestrating the subsequent immune response. IL-4 stimulates B-lymphocytes to produce and release large amounts of immunoglobulin E (IgE) antibodies specific to the allergen. IgE antibodies are specialized molecules that bind to mast cells and basophils, which are types of immune cells found in tissues throughout the body, including the nasal passages. During subsequent exposures to the same allergen, the allergen binds to the specific IgE antibodies attached to the mast cells and basophils.
This triggers the release of various chemical mediators from these cells, such as histamine, leukotrienes, and prostaglandins. Releasing chemical mediators leads to an inflammatory response in the nasal mucosa. Histamine causes blood vessels to dilate, leading to nasal congestion and swelling. It also triggers itching and stimulates the production of mucus. Leukotrienes and prostaglandins contribute to increased mucus production, bronchoconstriction, and further inflammation.
The etiology of allergic rhinitis involves a combination of genetic predisposition and environmental factors.
The prognosis of allergic rhinitis is generally good as it is a chronic condition that can be managed effectively with appropriate treatment and lifestyle modifications.
A comprehensive and detailed medical history is crucial in assessing allergic rhinitis (AR). It is important to ask specific questions about the nature of symptoms, their timing, duration, and frequency, any potential exposures, factors that worsen or alleviate symptoms, and any observed seasonal patterns.
Individuals with intermittent or seasonal AR commonly experience sneezing, rhinorrhea, and watery eyes. On the other hand, patients with chronic AR often present with complaints of postnasal drip, persistent nasal congestion, and obstruction. These individuals frequently have a family history of allergic rhinitis or a personal history of asthma.
Patients with intermittent rhinitis may provide information about triggers that initiate their symptoms, including allergens like pollen, animal dander, mold, dust mites, and irritants such as certain flooring or upholstery materials, high humidity levels, strong perfumes, or exposure to tobacco smoke.
While the diagnosis of allergic rhinitis is primarily based on clinical history, physical examination findings can provide additional information. The provider may observe nasal congestion or swelling of the nasal passages. The presence of clear, watery nasal discharge (rhinorrhea) may be noted. The provider may observe redness or swelling of the conjunctiva, the thin membrane covering the white part of the eyes.
Excessive tearing or watery eyes (epiphora) may be noted. Signs of postnasal drip and mucus dripping down the back of the throat can be observed. This can lead to throat irritation or cough. Dark circles or puffiness under the eyes, known as allergic shiners, may be present due to congestion of blood vessels in the area.
Vasomotor Rhinitis
Infectious Rhinitis
Nasopharyngeal Neoplasm
Nasal Polyposis
Identify and try to avoid allergens that trigger your symptoms. This may involve taking steps such as using dust mite-proof covers on bedding, keeping windows closed during high pollen seasons, and avoiding outdoor activities when pollen counts are high.
Medications such as antihistamines, nasal corticosteroids, and leukotriene receptor antagonists are commonly prescribed. Also, rinsing the nasal passages with a saltwater solution can help reduce nasal congestion and remove allergens and thin mucus.

Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.

On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.

When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
